{"id":"clopidogrel-asa-bivalirudin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL5314348","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel is a P2Y12 platelet inhibitor, ASA (aspirin) inhibits cyclooxygenase and platelet aggregation, and bivalirudin is a direct thrombin inhibitor. Together, they provide dual antiplatelet therapy plus anticoagulation, targeting multiple steps in the coagulation cascade to reduce thrombotic complications in acute coronary syndromes and percutaneous coronary intervention.","oneSentence":"This triple antiplatelet and anticoagulant combination inhibits platelet aggregation through multiple pathways while simultaneously blocking thrombin generation to prevent thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:30:15.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with percutaneous coronary intervention"},{"name":"Prevention of stent thrombosis"}]},"trialDetails":[{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT00669149","phase":"PHASE4","title":"Anticoagulant Treatments and Percutaneous Coronary Angioplasty","status":"TERMINATED","sponsor":"Centre Hospitalier de PAU","startDate":"2008-06","conditions":"Coronary Artery Disease","enrollment":99},{"nctId":"NCT02384070","phase":"NA","title":"Simplified Anti-Thrombotic Therapy for FFR","status":"COMPLETED","sponsor":"Odessa Heart Institute","startDate":"2009-01","conditions":"Coronary Artery Disease","enrollment":300},{"nctId":"NCT01642238","phase":"PHASE4","title":"Antithrombotic Effects of Ticagrelor Versus Clopidogrel","status":"COMPLETED","sponsor":"Juan J Badimon","startDate":"2012-07","conditions":"Acute Coronary Syndrome","enrollment":15},{"nctId":"NCT02268669","phase":"PHASE4","title":"Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI","status":"UNKNOWN","sponsor":"GRACIA Group","startDate":"2010-05","conditions":"Myocardial Infarction","enrollment":1444},{"nctId":"NCT00398463","phase":"PHASE4","title":"Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2006-05","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":263},{"nctId":"NCT01157455","phase":"PHASE4","title":"A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization","status":"UNKNOWN","sponsor":"CCRF Consulting Co., Ltd.","startDate":"2010-05","conditions":"Coronary Artery Diseases","enrollment":1900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plavix (clopidogrel)","Aspirin (ASA)","Angiomax (bivalirudin)"],"phase":"marketed","status":"active","brandName":"Clopidogrel + ASA + Bivalirudin","genericName":"Clopidogrel + ASA + Bivalirudin","companyName":"Juan J Badimon","companyId":"juan-j-badimon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple antiplatelet and anticoagulant combination inhibits platelet aggregation through multiple pathways while simultaneously blocking thrombin generation to prevent thrombotic events. Used for Acute coronary syndrome with percutaneous coronary intervention, Prevention of stent thrombosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}